Target intelligence / Profile preview

Myomesin-1 (MYOM1)

Target
MYOM1
Molecular classification
Other, Structural muscle protein, Fibronectin type III domain containing, Immunoglobulin superfamily domain containing
01

Overview

Myomesin-1 (MYOM1) is a large, structural protein encoded by the MYOM1 gene that forms an essential component of the M-band in striated muscle sarcomeres[1][3][5]. It cross-links adjacent myosin filaments and connects titin molecules, thereby maintaining the spatial organization and mechanical integrity of the sarcomere during contraction and relaxation. MYOM1 contains fibronectin type III and immunoglobulin-like domains, allowing dimerization and elasticity[1][2][6]. It is involved in mechano-signaling, energy homeostasis, and is critical for proper sarcomere assembly and muscle function[2][5]. Alternative splicing yields tissue- and disease-specific isoforms such as EH-myomesin, which are implicated in the adaptive response to cardiac stress and early stages of dilated cardiomyopathy[1][2][3]. MYOM1 is not known to be a therapeutic target or druggable protein, but its altered expression or splicing is associated with muscular and cardiac diseases, making it an emerging biomarker for muscle damage and disease progression[4][5].

Other names
Myomesin 1190 kDa connectin-associated protein190 kDa titin-associated proteinMyomesin family member 1SkeleminSKELEMINEH-myomesinMyomesin (M-protein) 1 (190kD)Myomesin 1 (skelemin) 185kDaMyomesin 1, 185kDa
02

Biological functions

Structural constituent of muscleCross-linking myosin filaments in the sarcomere M-bandSarcomere assembly and stabilizationEnergy homeostasis in muscleMediating stretch-induced signalingProtein dimerizationMechano-signaling
03

Disease associations

Cardiovascular disease (dilated cardiomyopathy, hypertrophic cardiomyopathy, myocardial atrophy)Muscular disease/myopathies (including muscular dystrophy, myotonic dystrophy type I)Other (structural and contractile defects in muscle)
04

Safety considerations

Not applicable for drug targeting as MYOM1 is not a current therapeutic target; knockout causes sarcomere collapse and muscle atrophy[5].
05

Biomarkers

Myomesin-1 as an early biomarker of sarcomere injury and muscle disease (potential)EH-myomesin splice variant as an indicator of dilated cardiomyopathy progression

Beyond the preview

Go deeper on Myomesin-1 (MYOM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myomesin-1 (MYOM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call